This biotechnology company develops RNA vaccines and precision cancer immunotherapies using a machine learning-driven design platform. They focus on creating novel therapeutics for infectious diseases like HCV and influenza, alongside treatments for solid tumors. The company operates an end-to-end platform encompassing generative protein design, mRNA architecture, and in-house GMP production capabilities.
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current mRNA vaccines against sarbecoviruses, including SARS-CoV-2, may not elicit sufficiently broad and potent antibody responses to protect against emerging variants. This necessitates the development of next-generation vaccines that can provide more robust and durable immunity against a wider range of viral threats.
Solution
PopVax is developing a novel mRNA vaccine platform that utilizes computational protein design and lipid nanoparticle (LNP) delivery systems to create broadly protective vaccines. Their approach involves a novel mRNA architecture for immunogen display on virus-like particles (VLPs), combined with PopVax-designed novel ionizable lipids for mRNA delivery. This platform aims to elicit significantly stronger antibody responses compared to existing vaccines, offering enhanced protection against current and future SARS-CoV-2 variants and other high-risk pathogens. The company's integrated R&D and GMP-capable clinical dose production facility facilitates rapid translation of new mRNA biomedicines from concept to clinic.
Target Audience
The primary target audience includes individuals and populations at risk of infection from SARS-CoV-2 variants and other infectious diseases, as well as public health organizations seeking advanced vaccine technologies for pandemic preparedness.
Features
- Novel mRNA architecture for immunogen display on virus-like particles (VLPs)
- LNP delivery platform using PopVax-designed novel ionizable lipids
- Machine learning-enabled computational approach to protein design
- Broadly-protective vaccine design targeting multiple strains of Influenza and the betacoronavirus genus
- Integrated R&D and GMP-capable clinical dose production facility
- Thermostable mRNA delivery formulation for improved vaccine stability
- Development of self-administered patch-delivered version of influenza vaccine